Varenicline for Smoking Cessation in the Bipolar Patient

TL;DRAbstract

Article Abstract Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text. To the Editor: I commend Chengappa and coauthors for their recent NIMH-funded, non-industry supported article revisiting the use of the selective α4β2 nicotinic acetycholine receptor partial agonist varenicline in patients with bipolar disorder. The accompanying thoughtful commentary by Goldberg is similarly appreciated. The Food and Drug Administration (FDA) does appear to hand out apparently damning black box warnings with alacrity, witness the citalopram and zolpidem edicts.

Chat with Paper

AI Agents for this Paper